` TCRX (TScan Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

T
TCRX
vs
S&P 500

Over the past 12 months, TCRX has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's +14% growth.

Stocks Performance
TCRX vs S&P 500

Loading
TCRX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TCRX vs S&P 500

Loading
TCRX
S&P 500
Difference
www.alphaspread.com

Performance By Year
TCRX vs S&P 500

Loading
TCRX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
TScan Therapeutics Inc vs Peers

S&P 500
TCRX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

TScan Therapeutics Inc
Glance View

Market Cap
50.8m USD
Industry
Biotechnology

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead liquid tumor TCR-T therapy candidates include TSC-100 and TSC-101, which are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation (HCT). TSC-100 and TSC-101 targets histocompatibility antigens (HA)-1 and HA-2 antigens, respectively. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. Its TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors. The firm's platform technologies include TargetScan, ReceptorScan and T-Integrate.

TCRX Intrinsic Value
3.4932 USD
Undervaluation 74%
Intrinsic Value
Price
T
Back to Top